ArticleThe Canadian journal of urology2026
Intraurethral cross-linked hyaluronic acid/dextranomer (DEXSUI®) injection versus mid-urethral sling for stress urinary incontinence: a comparative short-term outcome analysis.
Article in The Canadian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesStress urinary incontinence (SUI) is a prevalent condition that impairs quality of life; while midurethral sling (MUS) surgery is the standard treatment, intraurethral bulking injection offers a minimally invasive alternative. This study aimed to compare the efficacy and safety of intraurethral cross-linked hyaluronic acid/dextranomer (CLHA/Dx, DEXSUI®) injection with midurethral sling surgery in the treatment of stress urinary incontinence in women.
methodsThis retrospective study included women who presented with stress urinary incontinence to İzmir Bakırçay University, Çiğli Training and Research Hospital between January 2024 and June 2025. Patients underwent either midurethral sling surgery or intraurethral CLHA/Dx (DEXSUI®) injection. Exclusion criteria included urge incontinence, urinary tract infection, and BMI > 35 kg/m². Quality of life was assessed using the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), Urogenital Distress Inventory-6 (UDI-6), and Incontinence Quality of Life Questionnaire (I-QOL) questionnaires. Treatment success was defined by Patient Global Impression of Improvement (PGI)-I scores.
resultsMidurethral sling (MUS) was associated with significantly longer operative time (30.5 ± 7.8 vs. 11.4 ± 4.3 min, p < 0.001) and longer hospital stay (median 1 vs. 0 day, p < 0.001). At 1-month follow-up, complete dryness rates were similar (82.4% vs. 79.4%, p = 0.76). Both groups demonstrated significant improvement in ICIQ-SF, UDI-6, and Incontinence Quality of Life Questionnaire (I-QOL) scores compared with baseline (all p < 0.05), with slightly greater improvement observed in the MUS group; between-group differences were not statistically significant. Subgroup analysis by stress urinary incontinence (SUI) severity revealed consistently high dryness rates across mild, moderate, and severe categories, without significant intergroup differences.
conclusionsIntraurethral CLHA/Dx injection achieved clinical outcomes comparable to MUS, offering a less invasive alternative for SUI treatment.
Indexed as
Identifiers
42415582What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.